In vitro chemosensitivity testing of primary and recurrent breast carcinomas and its clinical significance

Abstract

In this study, in vitro chemosensitivity testing was conducted on primary cultured breast cancer cells from 96 patients with breast cancer, and the results showed that the cells from a few patients with primary breast cancer developed multidrug resistance (MDR) prior to the first chemotherapy exposure. All the cells from the recurrent cancer patients had MDR. The findings suggested that patients having MDR would benefit from high-dose chemotherapy (HDC) regimens. In vitro chemosensitivity screening, which was aimed at improving the therapeutic efficacy and minimizing side effects, helps in choosing individualized treatment for breast cancer.

Keywords

chemotherapy / breast cancer / primary culture / in vitro study

References

[1] ThomsonC. S., BrewsterD. H., DewarJ. A., et al.. Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur J Cancer, 2004, 40(5): 743-753

[2] LantzP. M., MujahidM., SchwartzK., et al.. The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis. Am J Public Health, 2006, 96(12): 2173-2178

[3] HofvindS., SørumR., ThoresenS.. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol, 2008, 47(2): 225-231

[4] PronzatoP., RondiniM.. First line chemotherapy of metastatic breast cancer. Ann Oncol, 2006, 17(Suppl5): v165-v168

[5] NicoliniA., GiardinoR., CarpiA., et al.. Metastatic breast cancer: an updating. Biomed Pharmacother, 2006, 60(9): 548-556

[6] RodenhuisS., BontenbalM., BeexL. V., et al.. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med, 2003, 349(1): 7-16

[7] TallmanM. S., GrayR., RobertN. J., et al.. Conventional adjuvant chemotherapy with or without high-fose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med, 2003, 349(1): 17-26

[8] PedrazzoliP., TarenziE., TullioC., et al.. High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer. J Chemother, 2004, 16(Suppl4): 108-111

[9] PetersW. P., RosnerG. L., VredenburghJ. J., et al.. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB. J Clin Oncol, 2005, 23(10): 2191-2200

[10] SeidmanA. D.. Current status of dose-dense chemotherapy for breast cancer. Cancer Chemother Pharmacol, 2005, 56(Suppl1): 78-83

[11] CharlotteK., TonyC., MinW., et al.. Reconstruction of functionally normal and malignant human breast tissues in mice. PNAS, 2004, 101(14): 4966-4971

[12] LiZ., HeY. L., ZhangJ. H., et al.. Determination of telmorase activity in stem cells and non-stem cells of breast cancer. Front Med China, 2007, 1(3): 294-298

[13] BakerE. K., El-OstaA.. MDR1, chemotherapy and chromatin remodeling. Cancer Biol Ther, 2004, 3(9): 819-824

[14] DuncanR., VicentM. J., GrecoF., et al.. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer, 2005, 12(Suppl1): S189-S199

[15] O’DriscollL., ClynesM.. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets, 2006, 6(5): 365-384

[16] KuoM. T.. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol, 2007, 608: 23-30

[17] BuchholzT. A., StiversD. N., StecJ., et al.. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J, 2002, 8(6): 461-468

[18] MoliterniA., Me’nardS., ValagussaP., et al.. HER2 overex-pression and doxorubicinin adjuvant chemotherapy for resectable breast cancer. J Clin Oncol, 2003, 21(3): 458-462

[19] AyersM., SymmansW. F., StecJ., et al.. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil,doxorubicin,and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol, 2004, 22(12): 2284-2293

[20] XiongH. H., YUS. Y., ZhuangL., et al.. Changes of survivin mRNA and protein expression during paclitaxel treatment in breast cancer cells. J Huazhong Univ Scien Techn [Med Sci], 2007, 27(1): 65-67

[21] LiQ. Q., WangW. J., XuJ. D., et al.. Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci, 2007, 98(11): 1767-1774

[22] FrederiksenL. J., SullivanR., MaxwellL. R., et al.. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res, 2007, 13(7): 2199-2206

[23] HardwickL. J., VelamakanniS., van VeenH. W.. The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol, 2007, 151(2): 163-174

[24] DoyleL. A., YangW., AbruzzoL. V., et al.. A multidrug resistance transporter from human MCF-7 breast cancer cells. PNAS, 1998, 95(26): 15665-15670

[25] SharomF. J., LiuR., QuQ., et al.. Exploring the structure and function of the P-glycoprotein multidrug transporter using fluorescence spectroscopic tools. Semin Cell Dev Biol, 2001, 12(3): 257-265

[26] Vazquez-MartinA., RoperoS., BrunetJ., et al.. Inhibition of Fatty Acid Synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol Rep, 2007, 18(4): 973-980

[27] Vazquez-MartinA., ColomerR., BrunetJ., et al.. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting ‘HER2 super-expression’ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol, 2007, 31(4): 769-776

[28] GilbertS. G.. Trastuzumab in breast cancer. N Engl J Med, 2006, 354(6): 640-644

[29] JoensuuH., Kellokumpu-LehtinenP. L., BonoP., et al.. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med, 2006, 354(8): 809-820

[30] LazaridisG., PentheroudakisG., PavlidisN.. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol, 2008, 66(1): 31-41

[31] DinhP., SotiriouC., PiccartM. J.. The evolution of treatment strategies: aiming at the target. Breast, 2007, 16(Suppl2): S10-S16

[32] XuJ. M., SongS. T., TangZ. M., et al.. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat, 1999, 53(1): 77-85

[33] MohajerG., LeeE. S., BaeY. H.. Enhanced intercellular retention activity of novel pH-sensitive polymeric micelles in wild and multidrug resistant MCF-7 cells. Pharm Res, 2007, 24(9): 1618-1627